scholarly journals Comparing the Estimated and Actual Cost of Disposable Surgical Equipment

2012 ◽  
Vol 94 (3) ◽  
pp. 1-3 ◽  
Author(s):  
P Vasudev ◽  
R Lowe ◽  
C Maxwell-Armstrong
Keyword(s):  
Cost Effective ◽  
Actual Cost ◽  
Budget Cuts ◽  
Surgical Equipment ◽  
Real Cost ◽  
Financial Climate ◽  
The Difference ◽  
Cost Efficient ◽  
The Cost ◽  
Disposable Equipment

In the current financial climate the NHS faces budget cuts. A good knowledge of the costs of the equipment used in theatres will allow more cost-efficient allocation of resources. The equipment used is dependent on the consultant surgeon leading the operation, with individual surgeons having their own preferences. For the efficient running of a department one would assume that the surgeons would have a working knowledge of the cost of equipment. This study looked at the awareness of surgeons of the cost of disposable equipment. It aimed to highlight the difference between the estimated and actual cost of disposable items, providing feedback to the surgeons so they become more aware of the real cost of their choices in order to help optimise use of equipment. This will hopefully lead to more cost-effective theatres.

Are SSRIs a Cost-Effective Alternative to Tricyclics?

1996 ◽  
Vol 168 (4) ◽  
pp. 404-409 ◽  
Author(s):  
Matthew Hotopf ◽  
Glyn Lewis ◽  
Charles Normand
Keyword(s):  
Cost Effectiveness ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Cost Effective ◽  
Drop Out ◽  
Attrition Rates ◽  
The Difference ◽  
Randomised Controlled ◽  
Meta Analyses ◽  
The Cost ◽  
Effectiveness Studies

BackgroundSelective serotonin reuptake inhibitors (SSRIs) are more expensive than tricyclics. Reports have suggested that SSRIs are cost-effective because they are better tolerated and safer in overdose.MethodA systematic review of all randomised controlled trials (RCTs), meta-analyses, and cost-effectiveness studies comparing SSRIs and tricyclic antidepressants (TCAs).ResultsNone of the RCTs provided an economic analysis and there were methodological problems in the majority which would preclude this approach. Meta-analyses suggest that clinical efficacy is equivalent but slightly fewer patients prescribed SSRIs drop out of RCTs. Cost-effectiveness studies have been based on crude ‘modelling’ approaches and over-estimate the difference in attrition rates and the cost of treatment failure. It appears impossible to evaluate the economic aspects of suicide because of its rarity.ConclusionsThere is no evidence to suggest that SSRIs are more cost-effective than TCAs. The debate will only be concluded when a prospective cost-effectiveness study is done in the setting of a large primary care based RCT.

Cost benefit analysis of measures to reduce industrial effluent discharges

2010 ◽  
Vol 62 (7) ◽  
pp. 1623-1628
Author(s):  
Åsa Sivard ◽  
Tomas Ericsson ◽  
Nippe Hylander ◽  
Magnus Karlsson ◽  
Mikael Malmaeus
Keyword(s):  
Organic Material ◽  
Cost Benefit Analysis ◽  
Industrial Effluent ◽  
Oxygen Demand ◽  
Cost Benefit ◽  
Cost Effective ◽  
Paper Mill ◽  
Pulp And Paper Mill ◽  
Cost Efficient ◽  
The Cost

In an environmentally harmonized society the most cost effective measures to reduce the total effluent discharges should be taken into account. Generalised discharge values are presented for organic material and nutrients in this paper. Depending on conditions in the receiving water any of these parameters can be the determining factor for the eutrophication and oxygen demand. These parameters can be generalized into equivalent loads of TOC, nitrogen or phosphorus by recalculation according to the Redfield ratio. The cost for reduction of organic material and nutrients from a pulp and paper mill is calculated as a cost per unit pollutant (cost equivalent). This cost equivalent is compared with alternative costs, expressed in the same way, for reduction of organic material and nutrients in adjacent industries, municipal treatment plants, impact from transportation, farming, air deposits etc. In order to find where the most cost efficient measures for the society should be taken the cost equivalent for the mill is compared with the alternative measures and their equivalent costs.

Getting through Grade 2: Predicting Children’s Early School Achievement in Rural South African Schools

1997 ◽  
Vol 21 (2) ◽  
pp. 331-348 ◽  
Author(s):  
Christine Liddell ◽  
John Lycett ◽  
Gordon Rae
Keyword(s):  
Predictive Model ◽  
Demographic Data ◽  
School Achievement ◽  
Cost Effective ◽  
Teacher Ratings ◽  
Second Grade ◽  
Cost Efficient ◽  
And Gender ◽  
Teachers And Parents ◽  
The Cost

Children in the second-grade classrooms of three rural schools ( n 150) completed a variety of psychometric and curriculum-based tests, and were rated by their teachers and parents on dimensions of their everyday behaviour; demographic data (e.g. socioeconomic status, presence of mother in the home) and biographical information (e.g. gender, age, birth order) were also collected for each child. Some of these data (e.g. child’s age and gender) were more cost-efficient to collect than others (e.g. parent ratings). Measures were evaluated in terms of their salience for constructing a multivariate model that would predict subsequent grade 2 outcome, with the most cost-effective variables being inserted first. In this way, both the cost-efficiency and predictive power of independent variables (IVs) were taken into consideration when attempting to build a predictive model. A model containing three IVs (scores on curriculum-based tests, teacher ratings of children’s attention span, and teacher ratings of helpfulness) ultimately predicted 51% of the variance in grade 2 outcome. These results demonstrate, first, that it is possible to build a relatively strong predictive model of grade 2 outcome, although not based on variables that are cheap and quick to measure. Second, that doing well in grade 2 is not so much a matter of having well-developed, broad-ranging psychometric abilities, but more a matter of mastering elements of the curriculum and behaving in ways that permit adaptation to the requirements of crowded and under-resourced African classrooms.

scholarly journals Clinically Useful and Cost-Effective of Recombinant Human Thrombopoietin in Treatment of Chemotherapy Induced Thrombocytopenia

2020 ◽  
Author(s):  
Wenxian Wang ◽  
Yibing Xu ◽  
Lan Shao ◽  
Zhengbo Song ◽  
Yiping Zhang
Keyword(s):  
Malignant Tumors ◽  
Treatment Plan ◽  
Cost Effective ◽  
Blood Platelet ◽  
Chemotherapy Drugs ◽  
Hospitalization Period ◽  
Critical Organ ◽  
The Difference ◽  
The Cost ◽  
Recombinant Human Thrombopoietin

Abstract BackgroundThe bone marrow suppression during chemotherapy will cause severe platelet decline in the human body, resulting in critical organ hemorrhage and intracranial hemorrhage. Therefore, the efficacy and economics of recombinant human thrombopoietin (rhTPO) in treating different degrees of thrombocytopenia caused by chemotherapy were analyzed. MethodsFrom January 2018 to July 2019, 233 with diagnosed lung cancer treated with the course of chemotherapy or chemoradiotherapy were enrolled. After treatment with chemotherapy or chemoradiotherapy, they all happened thrombocytopenia and received rhTPO. We divided patients into three groups according to the level of platelet decline. Changes in blood platelet count, treatment plan and cost performance between them were analyzed. ResultsOf all the included patients, 39.5% was undergoing concurrent radiotherapy or chemotherapy; 42.9% had thrombocytopenia of grade II; 40.3% had thrombocytopenia of grade III; 16.7% had thrombocytopenia of grade IV; 52.8% postponed the next cycle of chemotherapy or radiotherapy due to platelet decline; 12.0% changed the treatment plan for malignant tumors due to severe platelet decline; 15.5% reduced the dose of chemotherapy drugs due to thrombocytopenia; 23.6% had platelet transfusions during this period. During the extended hospitalization period caused by thrombocytopenia, the medical expenses of patients would increase significantly, which was dominated by the cost of rhTPO. ConclusionsFor different degrees of thrombocytopenia, the treatment of rhTPO could increase platelet counts effectively. During the treatment, patients might have varying degrees of economic and the difference between the treatment duration of different patients.

scholarly journals LABOR COSTS AND COST OF LABOR: CONCEPTS, TRENDS, INDICATORS

2018 ◽  
Vol 2018 (1) ◽  
pp. 3-15
Author(s):  
Gennadii KULIKOV ◽  
Keyword(s):  
Labor Force ◽  
Labor Cost ◽  
Structural Elements ◽  
Labor Costs ◽  
Real Cost ◽  
Additional Information ◽  
Goods And Services ◽  
Production Value ◽  
The Difference ◽  
The Cost

Concepts of “labor costs” and “cost of labor” have been refined. Differences between the concepts of “labor costs” and “total cost of labor”, “price of labor” and “wages”, “compensation” and “wages”, “labor costs” and “staff costs” are shown. The concept of “labor costs not belonging to the wage fund” is specified. Significance of these costs as a workforce reproduction factor in the system of social and labor relations is considered. Trends in labor costs and their structural elements in Ukraine and abroad are revealed and their comparative analysis is carried out. The difference between the “production value of labor force” (that is, “real cost of labor for producer”) and the “real consumer value of labor force” (that is, “real cost of labor for employee” as a consumer of goods and services) is justified. Differences in cost of labor indicators in Ukraine and the EU countries are shown and proposals to use new indicators are suggested. Recommendations on development of the system of accounting for the cost of labor in terms of its flexibility, efficiency and reliability are elaborated, in particular, concerning the quarterly accounting of cost of labor indices, hourly wages and labor cost levels. Purposes of using the statistical information on employer’s expenses for maintaining the workforce are determined. Indicators of the costs of maintaining the workforce were estimated by users of this information. The need of enterprises for additional information is justified.

Estimating the real cost of adjuvant (A) trastuxumab (T) in patients(pts) with HER-2+ (H+) early stage breast cancer (ESBC)

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 6081-6081
Author(s):  
E. Wilson ◽  
J. Crown ◽  
J. Ballot ◽  
D. McDonnell ◽  
E. Sheehan ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Relapse Rate ◽  
Early Stage ◽  
The Real ◽  
Real Cost ◽  
Molecular Therapies ◽  
Cost Efficient ◽  
Dose Dense ◽  
The Cost ◽  
Risk Of Relapse

6081 Background: Pts with H+ metastatic (M) ESBC have a high risk of relapse. T has been reported to reduce the risk of relapse for pts with H+ESBC by approximately 50% when combined with A chemotherapy (CT). We attempted to study the real cost of AT in the context of current use of T in MBC (MT), and of the predicted reduction in the risk of relapse. Methods: We conducted a retrospective analysis of the mean per pt cost of AT and MT, and standard ACT in St. Vincent’s Hospital. The costs/pt for AT and MT were €34k, and €47k respectively, and for the listed agents in standard A: docetaxel(D)-8.8k, paclitaxel(P)-7.4 k, filgrastim(G)-9.3 k. Based on published/presented data (BCIRG 001), we assumed a 35% risk for relapse at five years for pts with H+BC receiving conventional A, and a 50% risk reduction (RR) for AT, giving an absolute benefit of 17.5%. We then devised an equation to calculate the Crp for AT: Crp=[a-M(NRA/104)]/[NRA/104] where a = cost per pt for treatment (Tx) with AT, M = cost per pt for Tx with T in MBC, N = % of pts relapsing after standard A, RA = % reduction in the risk of relapse after Tx with AT (over standard A). Results: The corresponding real T costs/100 pts for the following reductions in relapse rate would be:25%-€3.4m 50%-€2.6m-, 80%-€2.1m, 100%-€1.8m. The Crp for AT with a 50% reduction in relapse rate is €147k. With a 100% reduction in the RR we estimate the Crp to be €50k. We studied D (D-BCIRG 001), P (P-CALGB 9344) and G (G-CALGB 9741 dose-dense), and noted the following published absolute relapse reductions for these tx: D-7%, P-5% and G-4%. The following costs per relapse prevented were calculated: P-148 k; G-231k; D-126k. Conclusions: Using the equation, the real cost per relapse prevented of AT can be calculated, and comparisons made with the cost-effectiveness of other accepted A. Assuming no re-treatment with MT, AT appears to be a relatively cost-efficient means of reducing relapses. Reports of the efficacy of short AT regimens suggest the possibility of even greater cost-effectiveness. This equation could possibly be used to calculate the cost effectiveness of other novel A molecular therapies. [Table: see text]

Estimating the real cost of adjuvant (adj) trastuzumab (T) in patients (pts) with HER-2+ (H+) early stage breast cancer (ESBC): Potential impact of reduced use of expensive oncology drugs (EOD) in metastatic breast cancer (MBC)

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 6534-6534
Author(s):  
R. O'Cearbhaill ◽  
E. Wilson ◽  
A. deFrein ◽  
Z. Qadir ◽  
D. McDonnell ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Stage ◽  
Metastatic Breast ◽  
Cost Effective ◽  
Societal Cost ◽  
University Hospital ◽  
The Real ◽  
Real Cost ◽  
The Mean ◽  
The Cost

6534 Background: Pts with H+ early stage BC have an approximately 35% risk of developing MBC (BCIRG001). T has been reported to reduce this risk by 33–50%, but costs approximately €;30k per pt, a burden some health systems deem unsustainable. This risk reduction might however result in decreased utilization of EOD in MBC, lowering the societal cost of adjT. We attempted to estimate the cost per relapse prevented (Crp), and the real cost of adjT, allowing for potential savings in prevented cases of MBC. Methods: We conducted a retrospective analysis of the mean cost per pt of AdjT (1 year) and of EOD in MBC in St. Vincent's University Hospital. We devised an equation to calculate the Crp for adj T. Crp=[A-M(NRA/104)]/[NRA/104] where A = cost per pt for adjT, M = EOD cost per pt with MBC, N = % of pts relapsing after standard adj treatment, RA = % reduction in the risk of relapse after adjT (over standard adj). Results: H+ pts with MBC received T (average 34 cycles €;2,400 each) with a combination of the following drugs: docetaxel (x8 €;1,500), gemcitabine (x5 €;1,215), capecitabine (x8 €;400), vinorelbine ( x19 €;187). Only 2 pts received bevacizumab (Bev) (x15 €;3,000). In our unit the mean EOD cost per pt with MBC was €;108k. The cost per relapse prevented for a 33% and a 50% reduction in relapse rate would be €;152k and €;63k, respectively. Furthermore, assuming a 50% reduction in the rate of relapse (from 35 to 17.5%) the real cost of adjT per pt treated is not €;30k, but approximates €;11k (€;30k×100-{17.5x €;108k}). Conclusions: The reduced utilization of EOD in MBC likely has a very beneficial impact on the societal cost of adjT. Confirmation of the efficacy of shorter adjT (e.g. FinnHer) would produce further benefit. The increasing use of novel EOD in MBC e.g. Bev would make adjT even more cost-effective. No significant financial relationships to disclose.

Home-based versus hospital-based care for serious mental illness

1998 ◽  
Vol 172 (6) ◽  
pp. 506-512 ◽  
Author(s):  
Martin R. J. Knapp ◽  
Isaac M. Marks ◽  
Jane Wolstenholme ◽  
Jennifer K. Beecham ◽  
Jack Astin ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Standard Care ◽  
Cost Effective ◽  
Controlled Study ◽  
Sample Attrition ◽  
Home Based ◽  
The Difference ◽  
Randomised Controlled ◽  
The Cost ◽  
Home Based Care

BackgroundThe Daily Living Programme (DLP) offered intensive home-based care with problem-centred case management for seriously mentally ill people facing crisis admission to the Maudsley Hospital, London. The cost-effectiveness of the DLP was examined over four years.MethodA randomised controlled study examined cost-effectiveness of DLP versus standard in/out-patient hospital care over 20 months, followed by a randomised controlled withdrawal of half the DLP patients into standard care. Three patient groups were compared over 45 months: DLP throughout the period, DLP for 20 months followed by standard care, and standard care throughout. Bivariate and multivariate analyses were conducted (the latter to standardise for possible inter-sample differences stemming from sample attrition and to explore sources of within-sample variation).ResultsThe DLP was more cost-effective than control care over months 1–20, and also over the full 45-month period, but the difference between groups may have disappeared by the end of month 45.ConclusionsThe reduction of the cost-effectiveness advantage for home-based care was perhaps partly due to the attenuation of DLP care, although sample attrition left some comparisons under-powered.

Cost-effective analysis of conventional and nurse-led clinics for common otological procedures

2004 ◽  
Vol 118 (3) ◽  
pp. 189-192 ◽  
Author(s):  
S. Uppal ◽  
J. Jose ◽  
P. Banks ◽  
E. Mackay ◽  
A. P. Coatesworth
Keyword(s):  
Cost Effective ◽  
Access Time ◽  
Patient Visit ◽  
Complex Patients ◽  
The Difference ◽  
The Cost ◽  
Mean Cost ◽  
Effective Health Care ◽  
Effective Analysis

The need to reduce costs while providing a first-class service has led to the expansion in the role of nurses in recent years. We present results of a comparison of the cost-effectiveness of conventional and nurse-led out-patient ear clinics. Our results indicate that cost-effective health care is a distinct competitive advantage for nurses taking up some roles conventionally performed by doctors. The difference in mean cost of out-patient visit per patient between the two groups is £75.28. This is equivalent to a reduction in cost to the hospital of more than £47000 for the 626 patients seen in a nurse-led ear clinic in a year. The nurse-led service is thus more cost-effective and presents an opportunity by freeing up otolaryngologists’ time to see more complex patients and has the potential for reducing out-patient access time in the NHS.

scholarly journals Comparative Analysis of Actual Cost and INA CBG Rate in Diabetic Gangrene Inpatients

2021 ◽  
Vol 8 (3) ◽  
pp. 284
Author(s):  
Diajeng Putri Kinanti ◽  
Umi Athiyah ◽  
Yunita Nita ◽  
Muhammad Noor Diansyah
Keyword(s):  
Financial Burden ◽  
Red Cross ◽  
Actual Cost ◽  
Test Results ◽  
Real Cost ◽  
Hospital Perspective ◽  
Cost Of Disease ◽  
Diabetic Gangrene ◽  
The Difference ◽  
System Objective

Background: Diabetic gangrene is a complication of diabetes mellitus that imposes a substantial financial burden on patients and their families as well as the health care system. Objective: To determine the total cost of disease, and the difference between real cost and INA CBG rate for diabetic gangrene inpatients from January - December 2017 at Universitas Airlangga Hospital, Surabaya Methods: The study was conducted retrospectively by using a total sampling method. The perspective used was the hospital perspective. This study's direct medical costs were laboratory, drug and consumable medical device costs, medical equipment rental, radiology examination, red cross, oxygen, service, and room costs. Data analysis was performed using an independent samples t-test. Results: The results showed that 148 patients met the inclusion criteria. The total real cost of diabetic gangrene inpatients at Universitas Airlangga Hospital in 2017 was IDR 1,339,949,381, and the total INA CBG rate for inpatients with diabetic gangrene was IDR 1,365,047,500. The difference was (p = 0.000) between real cost and INA CBG rate. Conclusion: There is a difference between the actual cost and the INA CBG rate for diabetic gangrene inpatients.

Sign in / Sign up

Export Citation Format

Share Document